Global Injection Peptide Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Injection Peptide Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are distinguished from proteins on the basis of size, and as a benchmark can be understood to contain approximately 50 amino acids or less.
Injection Peptide Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Injection Peptide Drug market is projected to reach US$ 62200 million in 2029, increasing from US$ 35410 million in 2022, with the CAGR of 9.0% during the period of 2024 to 2029. Demand from Cancer and Metabolic Disorders are the major drivers for the industry.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Injection Peptide Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Segment by Type
Intravenous Injection
Subcutaneous Injection
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Injection Peptide Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Injection Peptide Drug introduction, etc. Injection Peptide Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Injection Peptide Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Injection Peptide Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Injection Peptide Drug market is projected to reach US$ 62200 million in 2029, increasing from US$ 35410 million in 2022, with the CAGR of 9.0% during the period of 2024 to 2029. Demand from Cancer and Metabolic Disorders are the major drivers for the industry.
The Peptide Drug market is driven by the increasing recognition of peptides as a versatile and promising class of therapeutics. Peptides offer the potential to target specific biological pathways and cellular functions with high specificity, making them valuable candidates for treating a wide range of diseases, including cancer, metabolic disorders, and cardiovascular conditions. The growing understanding of peptide structure-activity relationships, coupled with advancements in peptide synthesis and modification techniques, contribute to the development of more stable and bioavailable peptide drugs, fostering market growth. Moreover, the rise in personalized medicine approaches and the need for more targeted therapies align with the development of peptide-based treatments that can be tailored to individual patient profiles. However, the market also faces challenges, including optimizing peptide delivery systems, enhancing bioavailability, and addressing potential immunogenicity and stability issues. Additionally, the complexity of peptide synthesis, the need for stringent regulatory approvals, and the competition from other therapeutic modalities pose obstacles for manufacturers and researchers. To succeed, stakeholders must focus on innovative peptide design, efficient synthesis methods, and comprehensive pre-clinical and clinical studies to demonstrate the safety and efficacy of peptide drugs. Addressing challenges while harnessing the therapeutic potential of peptides will be essential for driving the growth and adoption of peptide-based treatments in various medical applications.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Injection Peptide Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Segment by Type
Intravenous Injection
Subcutaneous Injection
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Injection Peptide Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Injection Peptide Drug introduction, etc. Injection Peptide Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Injection Peptide Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices